Taysha Gene Therapies, Inc. TSHA 深 滬
已收盤 10-03 16:00:00 美东时间
4.76
-0.120
-2.46%
華盛通- 最 高5.40
- 今 開5.05
- 成交量 1812.19万股
- 最 低 4.485
- 昨 收 4.88
- 總市值 12.99亿
- 52周最高 5.40
- 市盈率 靜 --
- 換手率 6.64%
- 52周最低 1.05
- 委 比 -94.89%
- 總股本 2.73亿
- 歷史最高 33.35
- 量 比 0.62
- 振 幅 18.75%
- 歷史最低 0.50
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | TSHA飙升超53%，试验性治疗获FDA突破性疗法认定；嘉楠科技大涨近27%
TSHA飙升超53%，试验性治疗获FDA突破性疗法认定；嘉楠科技大涨近27%，比特币重返12万美元叠加公司获得大规模矿机订单；ONDS涨26%，获国防无人机订单>>
10-03 19:10
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
SoundHound AI Stock Is Surging: What's Going On?
SoundHound AI Inc (NASDAQ:SOUN) shares are trading sharply higher Thursday. The stock may be benefiting from renewed investor attention to the company's recent industry recognition and strong revenue momentum.
10-03 01:44
FDA Grants Breakthrough Therapy Designation To Taysha Gene Therapies' TSHA-102 For Rett Syndrome; On Track To Begin Patient Enrollment In Q4 2025
Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trialsFinalized FDA alignment on REVEAL
10-02 20:03
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
Taysha Gene Therapies' TSHA-102 has received FDA Breakthrough Therapy designation for Rett syndrome, based on Part A clinical data showing a 100% response rate and favorable safety profile. The company has finalized pivotal trial protocol and SAP alignment, with a planned 6-month interim analysis that may expedite BLA submission. Patient enrollment is expected to begin in Q4 2025.
10-02 12:00
What's Driving the Market Sentiment Around Taysha Gene Therapies?
Taysha Gene Therapies's (NYSE:TSHA) short interest as a percent of float has ri...
09-19 01:00
Is Taysha Gene Therapies Gaining or Losing Market Support?
Taysha Gene Therapies's (NYSE:TSHA) short percent of float has fallen 13.08% si...
08-25 23:01
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Chardan Capital Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.
08-13 05:19
Taysha Gene Therapies Q2 EPS $(0.09) Misses $(0.08) Estimate, Sales $1.986M Beat $1.765M Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 9.76 percent. This is unchanged from the same period last year. The company
08-12 20:01
